Theravance Stock Rating Reaffirmed by Zacks

Theravance (NASDAQ:THRX)‘s stock had its “neutral” rating reiterated by Zacks in a research report issued on Friday. They currently have a $23.00 price objective on the stock. Zacks‘s price objective would indicate a potential upside of 4.55% from the company’s...

Christchurch patients wanted for health study

A world-first project overlaying real-time health data with air pollution information is taking off in Christchurch with the recruitment of citizen data collectors. The trust leading the project, Sensing City, wants to recruit 150 chronic obstructive pulmonary disease...